Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Delia Goletti

Showing results (11-20 of 310) with videos related to

Pageof 31
Sort By:
The Journal of Rheumatology. Supplement|May 3, 2014
Restarting biologics and management of patients with flares of inflammatory rheumatic disorders or psoriasis during active tuberculosis treatmentFabrizio Cantini, Francesca Prignano, Delia Goletti
The European Respiratory Journal|September 14, 2019
Global tuberculosis prevention: should we start from the beginning?Giovanni Sotgiu, Delia Goletti, Alberto Matteelli
Cold Spring Harbor Perspectives in Medicine|April 27, 2026
The Global Epidemiology of Tuberculosis: Burden, Trends, and DeterminantsGerhard Walzl, Delia Goletti, Alimuddin Zumla
American Journal of Respiratory and Critical Care Medicine|January 4, 2007
Should individuals who are tuberculin skin test negative and positive to RD1-IFN-gamma assay receive preventive therapy?Enrico Girardi, Delia Goletti, Giuseppe Ippolito
The Journal of Rheumatology. Supplement|May 3, 2014
Performance of the tuberculin skin test and interferon-γ release assays: an update on the accuracy, cutoff stratification, and new potential immune-based approachesDelia Goletti, Alessandro Sanduzzi, Giovanni Delogu
Frontiers in Immunology|September 4, 2023
Initial immune response after exposure to <i>Mycobacterium tuberculosis</i> or to SARS-COV-2: similarities and differencesAlessandra Aiello, Saeid Najafi-Fard, Delia Goletti
The European Respiratory Journal|September 2, 2016
Preliminary data on precision of QuantiFERON-TB Plus performanceDaniela Maria Cirillo, Lucia Barcellini, Delia Goletti
Expert Opinion on Drug Safety|December 19, 2019
The impact of the interleukin 12/23 inhibitor ustekinumab on the risk of infections in patients with psoriatic arthritisAlen Zabotti, Delia Goletti, Ennio Lubrano, et al.
Frontiers in Medicine|June 24, 2024
Editorial: Addressing tuberculosis infection: an essential step in the fight against tuberculosisMiguel Santin, Anete Trajman, Delia Goletti, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 15, 2008
T cell responses to commercial mycobacterium tuberculosis-specific antigens in HIV-infected patientsDelia Goletti, Stefania Carrara, Donatella Vincenti, et al.
Pageof 31

Showing results (11-20 of 310) with videos related to

Sort By:
Pageof 31
The Journal of Rheumatology. Supplement|May 3, 2014
Restarting biologics and management of patients with flares of inflammatory rheumatic disorders or psoriasis during active tuberculosis treatmentFabrizio Cantini, Francesca Prignano, Delia Goletti
The European Respiratory Journal|September 14, 2019
Global tuberculosis prevention: should we start from the beginning?Giovanni Sotgiu, Delia Goletti, Alberto Matteelli
Cold Spring Harbor Perspectives in Medicine|April 27, 2026
The Global Epidemiology of Tuberculosis: Burden, Trends, and DeterminantsGerhard Walzl, Delia Goletti, Alimuddin Zumla
American Journal of Respiratory and Critical Care Medicine|January 4, 2007
Should individuals who are tuberculin skin test negative and positive to RD1-IFN-gamma assay receive preventive therapy?Enrico Girardi, Delia Goletti, Giuseppe Ippolito
The Journal of Rheumatology. Supplement|May 3, 2014
Performance of the tuberculin skin test and interferon-γ release assays: an update on the accuracy, cutoff stratification, and new potential immune-based approachesDelia Goletti, Alessandro Sanduzzi, Giovanni Delogu
Frontiers in Immunology|September 4, 2023
Initial immune response after exposure to <i>Mycobacterium tuberculosis</i> or to SARS-COV-2: similarities and differencesAlessandra Aiello, Saeid Najafi-Fard, Delia Goletti
The European Respiratory Journal|September 2, 2016
Preliminary data on precision of QuantiFERON-TB Plus performanceDaniela Maria Cirillo, Lucia Barcellini, Delia Goletti
Expert Opinion on Drug Safety|December 19, 2019
The impact of the interleukin 12/23 inhibitor ustekinumab on the risk of infections in patients with psoriatic arthritisAlen Zabotti, Delia Goletti, Ennio Lubrano, et al.
Frontiers in Medicine|June 24, 2024
Editorial: Addressing tuberculosis infection: an essential step in the fight against tuberculosisMiguel Santin, Anete Trajman, Delia Goletti, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 15, 2008
T cell responses to commercial mycobacterium tuberculosis-specific antigens in HIV-infected patientsDelia Goletti, Stefania Carrara, Donatella Vincenti, et al.
Pageof 31